Jun Liu

Dr. Jun Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 May 2022 in Analytical Biochemistry
Verified
Journal Article
Closed access
JLJun Liu
Jun Liu
KLKaipeng Li
Kaipeng Li
PXPeng Xue
Peng Xue
JXJinyi Xu
Jinyi Xu

19 May 2020 in The Analyst
Verified
Journal Article
Closed access
PDF file
JLJun Liu
Jun Liu
CCCheng Cao
Cheng Cao
A sulfonamide-appended gemcitabine prodrug was newly produced. The prodrug was shown to efficiently distinguish GSH from cysteine and homocysteine. Upon reaction of this prodrug with GSH, which is relatively abundant in tumor cells, sulfonyl group cleavage occurred as well as active release of the drug GMC and a concomitant increase in the innate fluorescence intensity. As a proof of concept, colocalization experiments were carried out; these experiments demonstrated that the probe LHX resulted in, via receptor-mediated endocytosis, significantly improved therapeutic efficacy and few side effects. Thus, these results indicated the theranostic agent to be a promising “integrative” platform for efficient cancer therapy. The agent can be activated in real time, and not only be selectively monitored and localized by specific tumour cells, but also undergo cascaded cleavage to induce both a fluorogenic response and release of an active cytotoxic drug.

17 August 2021 in ChemMedChem
Verified
Journal Article
Closed access
JLJun Liu
Jun Liu
JWJinhua Wang
Jinhua Wang
SSShuang Si
Shuang Si
JXJinyi Xu
Jinyi Xu
PXPeng Xue
Peng Xue

23 November 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
JLJun Liu
Jun Liu
SSShuang Si
Shuang Si
JXJinyi Xu
Jinyi Xu
PXPeng Xue
Peng Xue
KLKaipeng Li
Kaipeng Li